These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
53. Comorbidities and Metabolic Derangement of NAFLD. Bang KB; Cho YK J Lifestyle Med; 2015 Mar; 5(1):7-13. PubMed ID: 26528424 [TBL] [Abstract][Full Text] [Related]
54. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620 [TBL] [Abstract][Full Text] [Related]
55. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818 [TBL] [Abstract][Full Text] [Related]